Possible Biomarkers To Predict Response In Patients With Myelodysplastic Syndromes (MDS) Or Acute Myeloid Leukemia (AML) Treated With 5-Azacitidine

被引：0
|
作者：
Kuendgen, Andrea
Mueller-Thomas, Catharina
Urbaniak, Petra
Lauseker, Michael
Haferlach, Torsten
Alpermann, Tamara
Albuquerque, Andreia
Kohlmann, Alexander
Schnittger, Susanne
Hildebrandt, Barbara
Royer-Pokora, Brigitte
Gattermann, Norbert
Haas, Rainer
Germing, Ulrich
Goetze, Katharina
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.2757.2757
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2757
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Molecular diagnostic testing patterns in patients (pts) with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) in the Connect MDS/AML Registry.
    George, Tracy
    Patel, Jay L.
    Abedi, Mehrdad
    Cogle, Christopher R.
    Erba, Harry Paul
    Garcia-Manero, Guillermo
    Grinblatt, David L.
    Kiselev, Pavel
    Komrokji, Rami S.
    Louis, Chrystal Ursula
    Maciejewski, Jaroslaw P.
    Nifenecker, Melissa
    Pollyea, Daniel Aaron
    Roboz, Gail J.
    Savona, Michael R.
    Scott, Bart L.
    Sekeres, Mikkael A.
    Steensma, David P.
    Thompson, Michael A.
    Foucar, Kathryn
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [42] REDIFINING MONOSOMY 20 BY MOLECULAR CYTOGENETICS IN 1.0 MYELODYSPLASTIC SYNDROMES/ACUTE MYELOID LEUKEMIA (MDS/AML) PATIENTS
    Bernasconi, P.
    Dambruoso, I.
    Boni, M.
    Zappatore, R.
    Cavigliano, P. M.
    Giardini, I.
    Calatroni, S.
    Rocca, B.
    Caresana, M.
    Tarantino, P.
    Lazzarino, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 273 - 273
  • [43] Low dose Vidaza and thalidomide is an effective combination for patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
    Westervelt, P.
    Amirifeli, S.
    Mehdi, M.
    Mumtaz, M.
    Alhomsi, S.
    Wang, S.
    Miron, P.
    Lata, C.
    Galili, N.
    Raza, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 354S - 354S
  • [44] 5-AZACITIDINE TREATMENT RESTORES RESPONSE TO EPOETIN THERAPY IN HIGH RISK MYELODYSPLASTIC (MDS) PATIENTS
    Volpe, M.
    Volpe, A.
    HAEMATOLOGICA, 2012, 97 : 588 - 589
  • [45] A new biomarker of response to 5-azacitidine therapy in MDS and AML patients: SIRPB1
    Guadagnuolo, Viviana
    Papayannidis, Cristina
    Lacobucci, Ilaria
    Simonetti, Giorgia
    Padella, Antonella
    Paolini, Stefania
    Abbenante, Mariachiara
    Parisi, Sarah
    Volpato, Francesca
    Sartor, Chiara
    Fontana, Maria Chiara
    Delledonne, Massimo
    Malagola, Michele
    Fili, Carla
    Russo, Domenico
    Grilli, Sandro
    Cavo, Michele
    Martinelli, Giovanni
    CANCER RESEARCH, 2015, 75
  • [46] SURVIVAL IN PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATMENT WITH 5-AZACITIDINE: EXPERIENCE OF A CENTER
    Busnego, M. T.
    Sanchez, A.
    Notario, C.
    Cabello, A.
    Oliva, A.
    Brena, J.
    Alberich, M. P.
    Gonzalez, H.
    Marrero, C.
    Rios, P.
    Figueroa, A.
    Hernanz, N.
    Rios, M.
    Leon, A.
    Hernandez, P.
    Hillebrand, P.
    Uribe, L.
    Mesa, M. C.
    HAEMATOLOGICA, 2019, 104 : 424 - 424
  • [47] Hospitalization rates in elderly, newly diagnosed acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) patients treated with azacitidine.
    Ueda, Masumi
    Gupta, Divya
    Caimi, Paolo Fabrizio
    Creger, Richard
    Little, Jane
    William, Basem M.
    Lazarus, Hillard M.
    De Lima, Marcos J. G.
    Cooper, Brenda W.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [48] CC-486 (Oral Azacitidine) Following Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) in Patients with Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)
    William, Basem M.
    de Lima, Marcos
    Oran, Betul
    Champlin, Richard
    Papadopoulos, Esperanza B.
    Giralt, Sergio
    Scott, Bart L.
    Hetzer, Joel
    Wang, Xiwei
    Laille, Eric
    Skikne, Barry S.
    Craddock, Charles
    BLOOD, 2014, 124 (21)
  • [49] Efficacy of 5-Azacitidine on IDH1/2 Acute Myeloid Leukemia/Myelodysplastic Syndromes and Correlation with 2-Hydroxyglutarate Production
    Willekens, Christophe
    Saada, Veronique
    Broutin, Sophie
    Delahousse, Julia
    Renneville, Aline
    Petrovanu, Cynthia
    Marzac, Christophe
    Micol, Jean-Baptiste
    Solary, Eric
    Pasquier, Florence
    Lazarovici, Julien
    Ribrag, Vincent
    Preudhomme, Claude
    Quivoron, Cyril
    Penard-Lacronique, Virginie
    Paci, Angelo
    de Botton, Stephane
    BLOOD, 2017, 130
  • [50] Changes in promoter methylation and gene expression in patients with MDS and MDS-AML treated with 5-azacitidine and sodium phenylbutyrate
    Gore, SD
    Baylin, SB
    Dauses, T
    Grever, MR
    Jiemjit, A
    Manning, J
    Miller, CB
    Murgo, AJ
    Zwiebel, JA
    Herman, JG
    BLOOD, 2004, 104 (11) : 137A - 137A
12345